The impact of switching once-weekly teriparatide to denosumab in osteoporosis patients

Miyagi, Masayuki; Fujimaki, Hisako; Naruse, Keiko; Suto, Kaori; Inoue, Gen; Nakazawa, Takahiro; Imura, Takayuki; Saito, Wataru; Uchida, Katsuhisa; Shirasawa, Eiki; Takahira, Naonobu; Takaso, Masashi

doi:10.1016/j.jos.2018.08.001

Cited by 4 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A multicenter, randomized, non-inferiority study has shown similar results [ 116 , 117 ], and a recent patient-level pooled analysis including four RCTs showed that switching to denosumab therapy was more effective in improving BMD compared to continuing bisphosphonate treatment in postmenopausal women [ 118 ], which is consistent with the observation that bisphosphonates do not show further increases in BMD after 3 years. Furthermore, two studies showed that BMD increased when switching from teriparatide to denosumab treatment [ 119 , 120 ], and a RCT including 94 postmenopausal women with osteoporosis showed that a combination of denosumab and teriparatide improved BMD more than treatment with either of the medications alone [ 121 ]. However, a prospective non-randomized clinical trial including participants with glucocorticoid-induced osteoporosis suggested that teriparatide might have some advantages over denosumab regarding BMD gains when switching to one of these medications after at least 2 years of bisphosphonate treatment [ 122 ].…”

Section: Typical Osteoporotic Medications Fracture Risk and Bone Mineral Density (Bmd)mentioning

confidence: 99%

The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density

Burgh

Keyser

Zillikens

et al. 2021

Drugs

View full text Add to dashboard Cite

Section: Typical Osteoporotic Medications Fracture Risk and Bone Mineral Density (Bmd)mentioning

confidence: 99%

The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density

Burgh

Keyser

Zillikens

et al. 2021

Drugs

View full text Add to dashboard Cite

“…To evaluate the effects of the denosumab treatment, many studies use TRACP-5b as a biomarker for bone resorption. [21][22][23][24] Previous research has shown that the concentration of TRACP-5b in blood increases with the increase in bone resorption and accurately reflects the state of bone resorption. 25 Our study revealed a significant positive correlation between the change in LBMD and the TRACP-5b level at the time of denosumab initiation.…”

Section: Discussionmentioning

confidence: 99%

“…To evaluate the effects of the denosumab treatment, many studies use TRACP‐5b as a biomarker for bone resorption 21–24 . Previous research has shown that the concentration of TRACP‐5b in blood increases with the increase in bone resorption and accurately reflects the state of bone resorption 25 .…”

Section: Discussionmentioning

confidence: 99%

Risk factors for nonresponse to 2 years of denosumab administration in patients with osteoporosis: A retrospective single‐center cohorts study

Yamamoto,

Nagao,

Nishizaki

et al. 2024

Health Science Reports

View full text Add to dashboard Cite

Background and AimsTo investigate the factors associated with changes in bone mineral density (BMD) and the incidence of fractures in osteoporotic patients treated with denosumab.MethodsThis retrospective study included 162 osteoporotic patients treated with denosumab for 24 months between 2013 and 2019. Patients were divided according to the changes in BMD as nonresponders (NL group: <3% increase in lumbar spine BMD [LBMD], NH group: <0% increase in femoral neck BMD [FNBMD]) or responders (RL group: ≥3% increase in LBMD, RH group: ≥0% increase in FNBMD).ResultsThe respective changes in the LBMD and FNBMD after 24 months of denosumab treatment were 9.3% (95% confidence interval [CI]: 8.1–10.6) and 3.3% (95% CI: 2.1–4.5). Twenty‐eight (17.3%) patients were in the NL group, and 134 (82.7%) were in the RL group. A history of bisphosphonate treatment was a risk factor for being in the NL group (odds ratio [OR]: 3.84, 95% CI: 1.38–10.71, p = 0.007; adjusted OR: 3.21, 95% CI: 1.01–10.19, p = 0.048). Although the NH (n = 48; 30.8%) and RH (n = 108; 69.2%) groups had similar baseline characteristics, the NH group had a significantly higher baseline FNBMD than the RH group (p = 0.003). The change in FNBMD was negatively associated with the FNBMD at baseline (r = −0.34, p < 0.001). No new osteoporotic fractures occurred in either group during follow‐up.ConclusionIn osteoporotic patients receiving denosumab treatment, a history of bisphosphonate treatment was a risk factor for a lack of increase in LBMD, and a higher FNBMD at baseline was negatively associated with the change in FNBMD.

show abstract

“…To evaluate the effects of the denosumab treatment, many studies use TRACP-5b as a biomarker for bone resorption [21][22][23][24]. Previous research has shown that the concentration of TRACP-5b in blood increases with the increase in bone resorption and accurately re ects the state of bone resorption [25] .…”

Section: Discussionmentioning

confidence: 99%

Risk Factors for Non-Response to 2 Years of Denosumab Administration in Patients with Osteoporosis: a retrospective cohort study

Yamamoto

Nagao

Nishizaki

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: To investigate the factors associated with changes in bone mineral density and the incidence of fractures in osteoporotic patients treated with denosumab.Methods: This retrospectively registered study included 162 osteoporotic patients treated with denosumab for 24 months between 2013 and 2019. Patients were divided according to the changes in BMD as non-responders (NL group: <3% increase in lumbar spine BMD [LBMD], NH group: <0% increase in femoral neck BMD [HBMD]) or responders (RL group: ≥3% increase in LBMD, RH group: ≥0% increase in HBMD).Results: The respective changes in the LBMD and HBMD after 24 months of denosumab treatment were 9.3% (95% confidence interval (CI): 8.1–10.6) and 3.3% (95% CI: 2.1–4.5). Twenty-eight (15.3%) patients were in the NL group, and 134 (82.7%) were in the RL group. A history of bisphosphonate treatment was a risk factor for being in the NL group (odds ratio [OR]: 3.84, 95% CI: 1.38–10.71, p=0.007; adjusted OR: 3.21, 95% CI: 1.01–10.19, p=0.048). Although the NH and RH groups had similar baseline characteristics, the NH group had a significantly higher baseline HBMD than the RH group (p=0.003). The change in HBMD was negatively associated with the HBMD at baseline (r=-0.34, p<0.001). No new osteoporotic fractures occurred in either group during follow-up.Conclusion: In osteoporotic patients receiving denosumab treatment, a history of bisphosphonate treatment was a risk factor for a lack of increase in LBMD, and a higher HBMD at baseline was negatively associated with the change in HBMD.

show abstract

The impact of switching once-weekly teriparatide to denosumab in osteoporosis patients

Cited by 4 publications

References 18 publications

The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density

The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density

Risk factors for nonresponse to 2 years of denosumab administration in patients with osteoporosis: A retrospective single‐center cohorts study

Risk Factors for Non-Response to 2 Years of Denosumab Administration in Patients with Osteoporosis: a retrospective cohort study

Contact Info

Product

Resources

About